AURA · XBRL financial data

Aura Biosciences financial statements, every fiscal year

The same tables from 5 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (AURA's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Research and development	25,161	42,238	65,232	73,302	90,300
General and administrative	10,089	18,057	19,759	22,814	22,491
Operating income (loss)	(35,250)	(60,295)	(84,991)	(96,116)	(112,791)
Other income (expense)	—	(5)	(76)	(120)	77
Income tax expense (benefit)	0	0	137	112	108
Net income (loss)	(35,251)	(58,763)	(76,408)	(86,919)	(106,191)
Earnings per share, basic USD per share	(8.95)	(1.96)	(1.93)	(1.75)	(1.76)
Earnings per share, diluted USD per share	(8.95)	(1.96)	(1.93)	(1.75)	(1.76)
Weighted average shares, basic thousands of shares	5,160	29,937	39,620	49,650	60,338
Weighted average shares, diluted thousands of shares	5,160	29,937	39,620	49,650	60,338

Fiscal years (AURA's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	149,063	121,582	41,063	31,693	59,515
Prepaid and other current assets	4,618	7,871	5,625	9,529	5,498
Total current assets	153,704	196,702	231,794	160,623	149,739
Property and equipment, net	5,251	5,371	3,150	3,215	2,624
Right-of-use asset	950	20,671	18,854	17,379	15,828
Total assets	160,030	223,935	255,075	182,503	169,430
Accounts payable	2,401	2,921	1,787	2,304	1,549
Total current liabilities	7,272	10,457	12,357	14,913	18,383
Lease liability, non-current	360	17,895	16,870	15,620	14,134
Total liabilities	7,715	28,352	29,227	30,533	32,517
Accumulated deficit	(152,137)	(210,900)	(287,308)	(374,227)	(480,418)
Total stockholders' equity	152,315	195,583	225,848	151,970	136,913
Total liabilities and equity	160,030	223,935	255,075	182,503	169,430
Common shares outstanding (cover page) thousands of shares	29,217	37,800	49,504	50,225	64,150

Fiscal years (AURA's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(35,251)	(58,763)	(76,408)	(86,919)	(106,191)
Stock-based compensation	2,307	6,412	8,772	11,722	14,317
Net cash from operating activities	(32,410)	(54,601)	(63,847)	(79,805)	(84,742)
Purchases of property and equipment	2,125	1,094	709	1,253	447
Net cash from investing activities	(2,125)	(67,869)	(113,963)	68,821	35,595
Proceeds from issuing common stock	78,697	86,650	—	0	46,517
Net cash from financing activities	166,259	95,629	97,290	1,595	77,155
Net change in cash	131,724	(26,841)	(80,520)	(9,389)	—

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Aura Biosciences	67,836	not reported	(32,501)*	103.7M	2.1 quarters	Q2 FY26 10-QJun 30, 2026
Nektar Therapeutics	39,267	10,131	(75,770)*	34.1M	9.0 quarters	Q2 FY26 10-QJun 30, 2026
Prothena Corp Public	288,193	1,010	(25,049)*	51.3M	11.5 quarters	Q2 FY26 10-QJun 30, 2026
Altimmune	63,008	not reported	(24,221)*	194.5M	13.5 quarters	Q2 FY26 10-QJun 30, 2026
Usana Health Sciences	168,560	223,273	23,319*	18.5M	—	Q2 FY26 10-QJul 4, 2026
Rigel Pharmaceuticals	60,816	78,703	30,653*	18.7M	—	Q2 FY26 10-QJun 30, 2026
Amarin	156,512	39,550	9,223*	not reported	—	Q3 FY26 10-QSep 30, 2026
Northwest Biotherapeutics	595	807	(7,169)*	1.7B	0.1 quarters	Q2 FY26 10-QJun 30, 2026
Siga Technologies	117,584	41,002	15,174*	71.8M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.